MannKind Corporation is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. The company develops and commercializes treatments for diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial portfolio includes Afrezza, an ultra rapid-acting inhaled insulin; Furoscix, a subcutaneous loop diuretic for edema; and the V-Go wearable insulin delivery device. MannKind also manufactures Tyvaso DPI, a dry-powder inhalation treatment for pulmonary arterial hypertension, in collaboration with United Therapeutics. The company utilizes proprietary Technosphere technology to formulate dry-powder inhalation products, including pipeline candidates MNKD-201 for idiopathic pulmonary fibrosis and MNKD-701 for bumetanide delivery. MannKind acquired scPharmaceuticals Inc. in October 2025 and V-Go from Zealand Pharma in May 2022. It commercializes its products in the United States and partners with Cipla Ltd. for the launch of Afrezza in India.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage mannkindcorp.com
Sector Healthcare IR page investors.mannkindcorp.com/sec-filings
Tags
inhaled insulin, dry powder inhalation, diabetes treatment, pulmonary hypertension, idiopathic pulmonary fibrosis, loop diuretics, drug-device combinations, orphan lung diseases, cardiometabolic diseases, subcutaneous infusion, Afrezza, Furoscix, V-Go, Tyvaso DPI, MNKD-1501, MNKD-201, MNKD-701, Technosphere, scPharmaceuticals Inc., Zealand Pharma A/S, Zealand Pharma US Inc., United Therapeutics Corporation, Cipla Ltd., Furoscix ReadyFlow Autoinjector, Dreamboat
Press page mannkindcorp.com/newsroom

Metrics

Valuation  
Market cap $ 1.254B
Market cap (USD) $ 1.254B
P/E -16.96
PEG —
P/BV -33.66
P/S 3.03
P/OCF -18.94
P/FCF -16.00
Dividend yield —
Turnover / mcap —
Returns  
ROE -11.5%
ROI 1.7%
ROIC 11.4%
Profit margin 1.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 82
Quality score -11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Revenue 348.966M 285.504M 198.962M 99.77M 75.442M 65.144M 63.038M 27.859M 11.745M 174.758M 0 — — 35K 50K 93K — — — — — —
Net profit 5.863M 27.588M -11.938M -87.4M -80.926M -57.24M -51.903M -86.975M -117.333M 125.664M -368.445M -198.382M -191.49M -169.366M -160.804M -170.56M — — — — — —
Free cash flow 13.689M 32.818M -8.347M -88.268M -73.175M -28.929M -91.048M -38.085M — -79.234M -67.517M -20.011M -136.719M -120.497M -130.695M -158.196M — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Share price 5.67 6.43 3.64 5.27 4.37 3.13 1.29 1.06 2.32 0.54 4.57 5.95 4.53 1.95 2.69 8.22 9 5.06 9.5 17.72 8.54 —
Price performance 12m -0.12 0.77 -0.31 0.21 0.4 1.43 0.22 -0.54 3.3 -0.88 -0.23 0.31 1.32 -0.28 -0.67 -0.09 0.78 -0.47 -0.46 1.07 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 302,000 2.79M 4.02M 3.51M 4.22M 4.99M 16.8M 14.9M 11.8M 38.4M
↳ YoY growth +1,213.0% +823.5% +44.0% -12.5% +20.1% +18.4% +236.4% -11.3% -20.8% +225.0%
↳ 5y CAGR -41.3% +183.6% +75.3% +43.2% +30.0% +27.4% +55.5%
Borrowings, current (USD) — — — 5.03M — — — — — —
Borrowings, non-current (USD) — — — 114M — — — — — —
Lease liabilities (USD) — — — 2.51M 1.2M 102M 111M 109M 14.1M 12.8M
Cash and deposits (USD) 22.9M 43.9M 71.2M 29.9M 67M 124M 69.8M 238M 46.3M 74.9M
Intangible assets (USD) — — — — — — 1.15M 1.07M 5.27M 5.07M
Right-of-use assets (USD) — — — — — 2.28M 6.71M 4.69M 13.1M 11.8M
Net debt (borrowings + leases - cash) (USD) — — — 91.5M — — — — — —
Cash flow detail
Operating cash flow (USD) -78.1M -64.8M -37.7M -88.5M -28.1M -61.7M -80.7M 34.1M 42.5M 18.3M
Purchases of property, plant and equipment (USD) -1.14M — -354,000 -2.57M -801,000 -11.5M -7.59M -42.4M -9.69M -4.57M
Change in receivables (cash effect) (USD) -302,000 -2.49M -1.34M 504,000 -705,000 -776,000 -11.8M 2.35M 2.65M -4.76M
Change in inventories (cash effect) (USD) -2.33M -3.3M -3.15M -558,000 -1.31M -4.08M -5.67M -11.3M -3.2M -6.62M
Change in payables (cash effect) (USD) -12.1M 3.8M -1.61M -593,000 793,000 1.37M 4.1M -1.47M -2.79M -16.7M
Interest paid (cash effect) (USD) -8.99M -7.73M -3.76M -1.76M -3.56M -11.3M -8.85M -18.3M -17.5M -14.7M
Income taxes paid (cash effect) (USD) — -51,000 -240,000 — — — — — -4.26M -1.71M
Share-based compensation (USD) 5.14M 4.85M 6.86M 6.2M 6.51M 12.2M 13.4M 17.6M 21.4M 24.2M
Operating cash flow before change in receivables (USD) -77.8M -62.3M -36.4M -89M -27.4M -60.9M -68.9M 31.7M 39.9M 23M
Free cash flow (OCF - PPE - intangibles) (USD) -79.2M — -38.1M -91M -28.9M -73.2M -88.3M -8.35M 32.8M 13.7M
Income detail
Research and development expense (USD) 14.9M 14.1M 8.74M 6.9M 6.25M 12.3M 19.7M 31.3M 45.9M 66.3M
↳ 5y CAGR -31.6% -32.6% -39.7% -41.4% -26.8% -3.8% +6.9% +29.1% +46.1% +60.4%
Total comprehensive income (USD) 126M -117M -87M -51.9M -57.3M -80.9M -87.4M -11.9M 28.7M 4.87M
Comprehensive income to owners (USD) 126M -117M -87M -51.9M -57.3M -80.9M -87.4M -11.9M 28.7M 4.87M
Reported Mar 16, 2017 Feb 27, 2018 Feb 26, 2019 Nov 4, 2020 Feb 25, 2021 Feb 23, 2023 Feb 23, 2023 Feb 26, 2025 Feb 26, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

11/05/26

PDF Version

  • Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025

  • Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025

  • Furoscix ReadyFlow™ was approved and shipments commenced mid-September

  • Rapid adoption of Furoscix ReadyFlow, making up approximately 75% of the current weekly Furoscix shipments

  • Afrezza® pediatric launch accounts for an approximately 80% increase in average monthly new-to-brand prescriptions in Q3 vs. Q2 2026

  • Pipeline Advancements

  • Reported positive Phase 1b INFLO-1 results, demonstrating tolerability of nintedanib DPI and clinical validation of Technosphere DPI technology in IPF; global Phase 2 trial underway

  • Conference call and webcast today at 4:30 p.m. ET

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: **MNKD)**a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the third quarter of 2026, and provided a business update.

“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them,” said Michael Castagna, Chief Executive Officer of MannKind. “We are focused on scaling two commercial launches while supporting three programs in IPF. Furoscix ReadyFlow is off to an exceptionally strong start, and we believe Furoscix will generate more revenue in the fourth quarter than it did in the first half of 2026. ReadyFlow significantly expands the opportunity ahead and reinforces our conviction that Furoscix can be transformational for MannKind and the patients we serve.”

Business Update Commercial Products Furoscix

  • Furoscix® generated $22.4 million in net revenue for the third quarter of 2026, with Furoscix ReadyFlow shipments commencing in mid-September

  • Approximately 75% of Furoscix shipments transitioned to ReadyFlow by late October, demonstrating rapid adoption following launch

  • Achieved record monthly prescribers and prescriptions in September, reflecting continued growth in Furoscix utilization

Afrezza

  • Afrezza® generated $19.3 million in net sales for the third quarter of 2026

  • Total prescriptions increased approximately 17% compared with Q2 2026, driven by strong early uptake following the pediatric launch

  • All 60 priority pediatric institutions have prescribed Afrezza, with approximately 2,000 pediatric patients treated since launch

Development Nintedanib DPI (MNKD-201)

  • Positive Phase 1b INFLO-1 results demonstrated tolerability of nintedanib DPI, validating the Technosphere® DPI platform in IPF

  • Advancing MNKD-201 into global Phase 2 trial

Ralinepag DPI (MNKD-1501)

  • Formulation work completed; United Therapeutics plans to pursue clinical development

  • Anticipate earning $15 million in milestone payments in 2027

Inhaled GLP-1 Program

  • Entered into a licensing and collaboration agreement with Rose Pharma to develop an inhaled rapid-acting, short-duration GLP-1 for weight management

Corporate Update

  • Cash, cash equivalents and investments as of September 30, 2026, totaled $96.6 million

  • Closed $50 million private placement on July 24, 2026; proceeds funded the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow

ThirdQuarter2026****Financial Results

Revenues

| | Three Months Ended September 30, | |

| | 2026 | | 2025 | | $ Change | | % Change | |

| Revenues | (Dollars in thousands) | |

| Afrezza | | 19,349 | | | 18,493 | | | 856 | | | 5 | % | |

| Furoscix | | 22,376 | | | — | | | 22,376 | | | N/A | | |

| V-Go | | 3,277 | | | 3,812 | | | (535 | ) | | (14 | %) | |

| Collaborations and services | | 19,405 | | | 26,506 | | | (7,101 | ) | | (27 | %) | |

| Royalties | | 37,463 | | | 33,319 | | | 4,144 | | | 12 | % | |

| Total revenues | $ | 101,870 | | $ | 82,130 | | $ | 19,740 | | | 24 | % | |

| | | | | | | | | | | | | | |

Total revenues for the third quarter of 2026 increased compared to the same period in the prior year primarily due to the addition of Furoscix to our product portfolio following the October 2025 acquisition of scPharma, as well as an increase in revenue from royalties. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI. The increase in total revenue was partially offset by a decrease in revenue from collaborations and services which was primarily attributable to decreased product sold to UT. UT provides notice of their subsequent year purchase quantity on or prior to October 15th of each year and quarterly revenue fluctuations reflect delivery timing rather than changes in annual order volume.

Operating Expenses and Other Financial Highlights

  • Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $11.2 million for the three months ended September 30, 2026, compared to $4.5 million for the same period in 2025.

  • The increase is primarily attributable to the inclusion of Furoscix into our product portfolio following the acquisition of scPharma in October 2025. The Furoscix on-body infusor has a lower gross margin percentage than Afrezza which resulted in a decrease in gross margin in the current period.

  • Research and development expenses were $14.4 million for the three months ended September 30, 2026, compared to $14.1 million for the same period in 2025, an increase of 2%.

  • The increase was primarily attributable to the development of Furoscix ReadyFlow, higher personnel costs following the acquisition of scPharma, and increased clinical development costs for MNKD-201. These increases were partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study.

  • Selling, general and administrative expenses were $61.4 million for the three months ended September 30, 2026, compared to $29.1 million for the same period in 2025, an increase of 111%.

  • The increase was primarily attributable to costs associated with the promotion and support of Furoscix, which was acquired from scPharma in October 2025, expansion of our field-based teams, and launch activities related to Furoscix ReadyFlow and the pediatric indication for Afrezza.

Nine Months Ended September 30, 2026

Revenues

| | Nine Months Ended September 30, | |

| | 2026 | | 2025 | | $ Change | | % Change | |

| Revenues | (Dollars in thousands) | |

| Afrezza | | 51,643 | | | 51,709 | | | (66 | ) | | (0 | %) | |

| Furoscix | | 60,061 | | | — | | | 60,061 | | | N/A | | |

| V-Go | | 9,188 | | | 12,023 | | | (2,835 | ) | | (24 | %) | |

| Collaborations and services | | 77,941 | | | 78,727 | | | (786 | ) | | (1 | %) | |

| Royalties | | 102,583 | | $ | 94,552 | | $ | 8,031 | | | 8 | % | |

| Total revenues | $ | 301,416 | | $ | 237,011 | | $ | 64,405 | | | 27 | % | |

| | | | | | | | | | | | | | |

Total revenues for the nine months ended September 30, 2026 increased compared to the same period in the prior year due to the addition of Furoscix to our product portfolio following the October 2025 acquisition of scPharma, as well as an increase in royalties. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.

Operating Expenses and Other Financial Highlights

  • Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $33.1 million for the nine months ended September 30, 2026, compared to $12.9 million for the same period in 2025.

  • The increase is primarily attributable to the inclusion of Furoscix into our product portfolio following the acquisition of scPharma in October 2025. The Furoscix on-body infusor has a lower gross margin percentage than Afrezza which resulted in a decrease in gross margin in the current period.

  • Research and development expenses were $49.6 million for the nine months ended September 30, 2026, compared to $38.8 million for the same period in 2025, an increase of 28%.

  • The increase was primarily attributable to the development of Furoscix ReadyFlow, higher personnel costs following the acquisition of scPharma, and increased clinical development costs for MNKD-201. These increases were partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study.

  • Selling, general and administrative expenses were $173.8 million for the nine months ended September 30, 2026, compared to $85.7 million for the same period in 2025, an increase of 103%.

  • The increase was primarily attributable to costs associated with the promotion and support of Furoscix, expansion of our field-based teams, and launch activities related to Furoscix ReadyFlow and the pediatric indication for Afrezza.

Conference Call and Webcast MannKind will host a conference call and webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast can be accessed live via the Events & Presentations section of MannKind’s Investor Relations website. A replay will remain available in the same location for approximately 90 days following the conference call.

About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

Forward-Looking Statements Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the anticipated growth potential for Furoscix, including as a major commercial brand; the development plans for ralinepag DPI and the expected timing for milestone payments related thereto; the potential benefits of and opportunities for MannKind’s products and product candidates; and expectations regarding MannKind’s ongoing and planned clinical trials and nonclinical studies, including the ongoing Phase 2 INFLO-2 trial. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “goal,” “potential,” “prepare,” “opportunity” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data; risks associated with safety and other complications of our products and product candidates; risks associated with the regulatory review process; risks associated with competition; manufacturing risks; market adoption risks; and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Tyvaso DPI is a trademark of United Therapeutics Corporation.

AFREZZA, FUROSCIX, MANNKIND, and V-GO are registered trademarks, and Furoscix ReadyFlow is a trademark of MannKind Corporation.

| MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |

| | 2026 | | 2025 | | 2026 | | 2025 | |

| | (In thousands except per share data) | |

| Revenues: | | | | | | | | | | | | |

| Commercial product sales | $ | 45,002 | | | $ | 22,305 | | | $ | 120,892 | | | $ | 63,732 | | |

| Collaborations and services | | 19,405 | | | | 26,506 | | | | 77,941 | | | | 78,727 | | |

| Royalties | | 37,463 | | | | 33,319 | | | | 102,583 | | | | 94,552 | | |

| Total revenues | | 101,870 | | | | 82,130 | | | | 301,416 | | | | 237,011 | | |

| Expenses: | | | | | | | | | | | | |

| Cost of goods sold – commercial, excluding amortization of acquired intangible assets | | 11,213 | | | | 4,498 | | | | 33,130 | | | | 12,873 | | |

| Cost of revenue – collaborations and services | | 12,299 | | | | 15,705 | | | | 37,393 | | | | 45,414 | | |

| Research and development | | 14,360 | | | | 14,063 | | | | 49,592 | | | | 38,760 | | |

| Selling, general and administrative | | 61,412 | | | | 29,088 | | | | 173,801 | | | | 85,724 | | |

| Amortization of acquired intangible assets | | 5,160 | | | | — | | | | 13,895 | | | | — | | |

| (Gain) loss on foreign currency transaction | | (391 | ) | | | (120 | ) | | | (2,195 | ) | | | 7,752 | | |

| Total expenses | | 104,053 | | | | 63,234 | | | | 305,616 | | | | 190,523 | | |

| (Loss) income from operations | | (2,183 | ) | | | 18,896 | | | | (4,200 | ) | | | 46,488 | | |

| Other income (expense): | | | | | | | | | | | | |

| Interest income | | 1,090 | | | | 2,628 | | | | 3,541 | | | | 6,416 | | |

| Interest expense | | (7,642 | ) | | | (1,364 | ) | | | (27,015 | ) | | | (6,294 | ) | |

| Interest expense on liability for sale of future royalties | | (501 | ) | | | (3,514 | ) | | | (3,573 | ) | | | (10,564 | ) | |

| Interest expense on financing liability | | (2,434 | ) | | | (2,456 | ) | | | (7,241 | ) | | | (7,299 | ) | |

| Impairment of available-for-sale investment | | — | | | | (6,409 | ) | | | — | | | | (6,409 | ) | |

| Loss on settlement of debt | | — | | | | — | | | | (917 | ) | | | — | | |

| Other expense, net | | (11,503 | ) | | | — | | | | (19,271 | ) | | | — | | |

| Total other expense, net | | (20,990 | ) | | | (11,115 | ) | | | (54,476 | ) | | | (24,150 | ) | |

| (Loss) income before income tax expense (benefit) | | (23,173 | ) | | | 7,781 | | | | (58,676 | ) | | | 22,338 | | |

| Income tax expense (benefit) | | 51 | | | | (204 | ) | | | 198 | | | | 527 | | |

| Net (loss) income | $ | (23,224 | ) | | $ | 7,985 | | | $ | (58,874 | ) | | $ | 21,811 | | |

| Net (loss) income per share – basic | $ | (0.07 | ) | | $ | 0.03 | | | $ | (0.19 | ) | | $ | 0.07 | | |

| Weighted average shares used to compute net (loss) income per share – basic | | 320,182 | | | | 306,806 | | | | 312,722 | | | | 305,093 | | |

| Net (loss) income per share – diluted | $ | (0.07 | ) | | $ | 0.03 | | | $ | (0.19 | ) | | $ | 0.07 | | |

| Weighted average shares used to compute net (loss) income per share – diluted | | 320,182 | | | | 311,638 | | | | 312,722 | | | | 313,339 | | |

| | | | | | | | | | | | | | | | | |

| MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS |

| | | | | |

| | September 30, 2026 | | December 31, 2025 | |

| | (In thousands except share****and per share data) | |

| ASSETS | | | | | | |

| Current assets: | | | | | | |

| Cash and cash equivalents | $ | 41,276 | | | $ | 74,882 | | |

| Short-term investments | | 55,333 | | | | 96,464 | | |

| Accounts receivable, net | | 41,034 | | | | 38,367 | | |

| Inventory | | 48,469 | | | | 35,313 | | |

| Prepaid expenses and other current assets | | 54,364 | | | | 46,553 | | |

| Total current assets | | 240,476 | | | | 291,579 | | |

| Restricted cash | | 749 | | | | 745 | | |

| Property and equipment, net | | 86,371 | | | | 82,423 | | |

| Goodwill | | 67,595 | | | | 67,595 | | |

| Developed technology - Furoscix | | 305,877 | | | | 190,027 | | |

| IPR&D - ReadyFlow Formulation | | — | | | | 129,600 | | |

| Other intangible assets | | 4,927 | | | | 5,072 | | |

| Other assets | | 16,621 | | | | 20,129 | | |

| Long-term investments | | — | | | | 5,012 | | |

| Total assets | $ | 722,616 | | | $ | 792,182 | | |

| | | | | | | |

| LIABILITIES AND STOCKHOLDERS' DEFICIT | | | | | | |

| Current liabilities: | | | | | | |

| Accounts payable | $ | 14,383 | | | $ | 9,034 | | |

| Accrued expenses and other current liabilities | | 59,593 | | | | 64,628 | | |

| Liability for sale of future royalties – current | | 14,573 | | | | 14,298 | | |

| Financing liability – current | | 10,565 | | | | 10,328 | | |

| Deferred revenue – current | | 9,410 | | | | 15,331 | | |

| Contingent consideration – current | | — | | | | 21,132 | | |

| Senior convertible notes – current | | — | | | | 36,280 | | |

| Total current liabilities | | 108,524 | | | | 171,031 | | |

| Liability for sale of future royalties – long term | | 130,026 | | | | 136,985 | | |

| Financing liability – long term | | 92,231 | | | | 93,092 | | |

| Deferred revenue – long term | | 34,809 | | | | 39,977 | | |

| Recognized loss on purchase commitments – long term | | 63,720 | | | | 65,952 | | |

| Operating lease liability | | 9,177 | | | | 10,689 | | |

| Milestone liabilities | | 1,580 | | | | 2,003 | | |

| Term loan | | 319,447 | | | | 318,361 | | |

| Other long term liabilities | | 368 | | | | — | | |

| Contingent consideration – long term | | — | | | | 5,114 | | |

| Total liabilities | | 759,882 | | | | 843,204 | | |

| Commitments and contingencies | | | | | | |

| Stockholders' deficit: | | | | | | |

| Undesignated preferred stock, $0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2026 or December 31, 2025 | | — | | | | — | | |

| Common stock, $0.01 par value – 800,000,000 shares authorized; 321,633,894 and 307,832,587 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | | 3,216 | | | | 3,078 | | |

| Additional paid-in capital | | 3,214,437 | | | | 3,141,741 | | |

| Accumulated other comprehensive (loss) income | | (88 | ) | | | 115 | | |

| Accumulated deficit | | (3,254,831 | ) | | | (3,195,956 | ) | |

| Total stockholders' deficit | | (37,266 | ) | | | (51,022 | ) | |

| Total liabilities and stockholders' deficit | $ | 722,616 | | | $ | 792,182 | | |

| | | | | | | | | |

Non-GAAP Measures

To supplement our condensed consolidated financial statements presented under GAAP, we are presenting non-GAAP net (loss) income and non-GAAP net (loss) income per share – basic, which are non-GAAP financial measures. We are providing these non-GAAP financial measures to disclose additional information to facilitate the comparison of past and present operations, and they are among the indicators management uses as a basis for evaluating our financial performance. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our non-GAAP financial measures; and we may in the future cease to exclude items that we have historically excluded for purposes of our non-GAAP financial measures. Likewise, we may determine to modify the nature of adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized definitions of non- GAAP financial measures, the non-GAAP financial measures as used by us in this report have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

The following table reconciles our financial measures for net (loss) income and net (loss) income per share ("EPS") for basic weighted average shares as reported in our condensed consolidated statement of operations to a non-GAAP presentation:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |

| | 2026 | | 2025 | | 2026 | | 2025 | |

| | Net Loss | | Basic EPS | | Net Income | | Basic EPS | | Net Loss | | Basic EPS | | Net Income | | Basic EPS | |

| | | | | | | | | | | | | | | | | | | | | | | | | |

| GAAP reported net (loss) income | $ | (23,224 | ) | | $ | (0.07 | ) | | $ | 7,985 | | | | 0.03 | | | $ | (58,874 | ) | | $ | (0.19 | ) | | $ | 21,811 | | | $ | 0.07 | | |

| Non-GAAP adjustments: | | | | | | | | | | | | | | | | | | | | | | | | |

| Stock compensation | | 6,444 | | | | 0.02 | | | | 4,318 | | | | 0.01 | | | | 23,125 | | | | 0.07 | | | | 17,223 | | | | 0.06 | | |

| Interest expense on liability for sale of future royalties | | 501 | | | | 0.00 | | | | 3,514 | | | | 0.01 | | | | 3,573 | | | | 0.01 | | | | 10,564 | | | | 0.03 | | |

| Sold portion of royalty revenue (1) | | (3,746 | ) | | | (0.01 | ) | | | (3,332 | ) | | | (0.01 | ) | | | (10,258 | ) | | | (0.03 | ) | | | (9,455 | ) | | | (0.03 | ) | |

| (Gain) loss on foreign currency transaction | | (391 | ) | | | 0.00 | | | | (120 | ) | | | 0.00 | | | | (2,195 | ) | | | (0.01 | ) | | | 7,752 | | | | 0.03 | | |

| Amortization of intangible assets acquired | | 5,160 | | | | 0.01 | | | | — | | | | — | | | | 13,895 | | | | 0.05 | | | | — | | | | — | | |

| Expense related to contingent consideration | | 11,641 | | | | 0.04 | | | | — | | | | — | | | | 19,409 | | | | 0.07 | | | | — | | | | — | | |

| Loss on settlement of debt | | — | | | | — | | | | — | | | | — | | | | 917 | | | | 0.00 | | | | — | | | | — | | |

| Acquisition related expenses (2) | | — | | | | — | | | | 3,673 | | | | 0.01 | | | | — | | | | — | | | | 3,673 | | | | 0.01 | | |

| Impairment loss on available-for-sale investment | | — | | | | — | | | | 6,409 | | | | 0.02 | | | | — | | | | — | | | | 6,409 | | | | 0.02 | | |

| Non-GAAP adjusted net (loss) income | $ | (3,615 | ) | | $ | (0.01 | ) | | $ | 22,447 | | | $ | 0.07 | | | $ | (10,408 | ) | | $ | (0.03 | ) | | $ | 57,977 | | | $ | 0.19 | | |

| Weighted average shares used to compute net (loss) income per share – basic | | 320,182 | | | | | | | 306,806 | | | | | | | 312,722 | | | | | | | 305,093 | | | | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| (1) Represents the non-cash portion of the 1% royalty on net sales of Tyvaso DPI earned during the three and nine months ended September 30, 2026 and 2025 which is remitted to the royalty purchaser and recognized as royalties from collaborations in our condensed consolidated statements of operations. |

MannKind Contacts: Investor Relations Kate Miranda Email: [email protected] Media Relations Christie Iacangelo Email: [email protected]

Primary Logo

Source: MannKind

Company Logo

Do Not Sell or Share My Personal Data

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Opt Out of Sale of Sharing/Targeted Advertising

Opt Out of Sale of Sharing/Targeted Advertising

As a California consumer, you have the right to opt-out from the sale or sharing of your personal information at any time across business platform, services, businesses and devices. You can opt-out of the sale and sharing of your personal information by using this toggle switch. As a Virginia, Utah, Colorado and Connecticut consumer, you have the right to opt-out from the sale of your personal data and the processing of your personal data for targeted advertising. You can opt-out of the sale of your personal data and targeted advertising by using this toggle switch. For more information on your rights as a United States consumer see our privacy notice.

  • Targeting Cookies

Switch Label label

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

10/29/26

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.

MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2026, to discuss the financial results and provide a business update.

A live webcast of the conference call will be available in the Events & Presentations section of MannKind’s Investor Relations website. A replay will remain available in the same location for approximately 90 days following the conference call.

10/14/26

PDF Version

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference.

Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, CF, Bronchiectasis & COPD Innovation Date: Tuesday, October 20, 2026 Time: 2:00–2:30 p.m. ET

A live webcast of the panel discussion will be available on the Events & Presentations section of MannKind’s Investor Relations website. A replay of the webcast will be available on the website for approximately 90 days following the conference.

About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

Contacts: Investor Relations Kate Miranda [email protected] Media Relations Christie Iacangelo [email protected]

Primary Logo

Company Logo

Do Not Sell or Share My Personal Data

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Opt Out of Sale of Sharing/Targeted Advertising

Opt Out of Sale of Sharing/Targeted Advertising

As a California consumer, you have the right to opt-out from the sale or sharing of your personal information at any time across business platform, services, businesses and devices. You can opt-out of the sale and sharing of your personal information by using this toggle switch. As a Virginia, Utah, Colorado and Connecticut consumer, you have the right to opt-out from the sale of your personal data and the processing of your personal data for targeted advertising. You can opt-out of the sale of your personal data and targeted advertising by using this toggle switch. For more information on your rights as a United States consumer see our privacy notice.

  • Targeting Cookies

Switch Label label

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

Prompts

MannKind Corporation (ticker MNKD), listed in United States.

ETFs Holding MannKind Corporation

ETF Weight in ETF Shares Market value As of
JSMD 0.62% 1,678,187 $ 6.562M Jul 31, 2026
JSML 0.49% 450,643 $ 1.762M Jul 31, 2026
PSC 0.06% 354,917 $ 1.512M Jun 30, 2026
RESM 0.04% 343 $ 1,461.18 Jun 30, 2026
MSSM 0.01% 11,295 $ 45.293K Aug 31, 2026
DFAC 0.00% 207,439 $ 862.946K Nov 12, 2026
FESM 0.00% 4,364 $ 18.591K Jun 30, 2026
AVUQ 0.00% 1,330 $ 5,260.15 Nov 16, 2026